Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A).
Katayama H, Mizusawa J, Fukuda H, Nakamura S, Nakamura K, Saijo N, Yokoyama A, Ohe Y, Shinkai T, Nakagawa K, Abe T, Mitsuoka S, Okamoto H, Yamamoto N, Yoshioka H, Ando M, Tamura T, Takeda K. Katayama H, et al. Among authors: mitsuoka s. Jpn J Clin Oncol. 2021 Apr 30;51(5):685-692. doi: 10.1093/jjco/hyaa257. Jpn J Clin Oncol. 2021. PMID: 33479759 Clinical Trial.
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, Matsui K, Negoro S, Nakagawa K, Fukuoka M. Yoshimura N, et al. Among authors: mitsuoka s. Lung Cancer. 2006 Mar;51(3):363-8. doi: 10.1016/j.lungcan.2005.10.006. Epub 2005 Dec 20. Lung Cancer. 2006. PMID: 16364494 Clinical Trial.
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M. Tamura K, et al. Among authors: mitsuoka s. Cancer Chemother Pharmacol. 2007 Jul;60(2):285-93. doi: 10.1007/s00280-006-0382-7. Epub 2006 Nov 30. Cancer Chemother Pharmacol. 2007. PMID: 17136542 Clinical Trial.
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Yoshimura N, Okishio K, Mitsuoka S, Kimura T, Kawaguchi T, Kobayashi M, Hirashima T, Daga H, Takeda K, Hirata K, Kudoh S. Yoshimura N, et al. Among authors: mitsuoka s. J Thorac Oncol. 2013 Jan;8(1):96-101. doi: 10.1097/JTO.0b013e3182762bfb. J Thorac Oncol. 2013. PMID: 23207920 Free article. Clinical Trial.
89 results